HyperSight Imaging for Pelvic Cancer

Overseen By Sean Davidson

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Varian, a Siemens Healthineers Company

Disqualifiers: Vulnerable populations, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

40 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

Cone beam computed tomography (CBCT) images are routinely used in radiation treatment delivery workflows to align patients with the treatment beam. Conventional CBCT image quality is sufficient for this task but not good enough for other radiotherapy-related tasks, such as contouring anatomical structures and calculating radiation dose distributions. HyperSight is a new CBCT imaging system manufactured by Varian Medical Systems. The purpose of this study is to evaluate the integration of the HyperSight imaging system with Varian's TrueBeam radiotherapy system, a linear accelerator with a C-arm gantry that rotates about the patient to delivery radiation to the target malignancy. HyperSight CBCT images will be acquired prospectively from patients who are receiving radiation treatment. The HyperSight/TrueBeam system will be used for imaging only; patients receive their radiation treatment on cleared devices and no aspect of their treatment is affected by participation in the study. HyperSight images collected during the study will be evaluated for quality and utility and compared to conventional CBCT images as well as fan beam CT images used for treatment planning.

Are You a Good Fit for This Trial?

This trial is for adults who are set to receive radiation therapy for cancers in the head, neck, thorax, abdomen, or pelvis. They must have good kidney function if receiving IV contrast and women of childbearing age need a negative pregnancy test. It's not open to those unable to consent or considered vulnerable.

Inclusion Criteria

My kidneys work well enough for IV contrast, with an eGFR over 30.

I can join the study without a kidney test if I'm not getting IV contrast.

I am scheduled for radiation therapy on my head, neck, chest, abdomen, or pelvis.

Exclusion Criteria

Patient is unwilling or unable to sign an IRB-approved written informed consent document

I am not in a position to fully understand or decide about participating in this study without influence.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Imaging

Participants are imaged with the new HyperSight CBCT imaging system to evaluate integration with the TrueBeam radiotherapy system

1-9 weeks

Multiple imaging sessions

Follow-up

Participants are monitored for image quality and utility in radiotherapy workflow

1-9 weeks

What Are the Treatments Tested in This Trial?

Interventions

• HyperSight imaging

Trial Overview The study tests HyperSight imaging integrated with the TrueBeam radiotherapy system by Varian Medical Systems. The goal is to see if this new CBCT imaging can provide clearer images than conventional methods without affecting patients' ongoing radiation treatments.

How Is the Trial Designed?

Group I: HyperSight Imaging arm Experimental Treatment 1 Intervention

Subjects are imaged with the new HyperSight CBCT imaging system.

Who Is Running the Clinical Trial?

Varian, a Siemens Healthineers Company

Lead Sponsor

Trials

35

Recruited

7,200+